The ATM tumour suppressor gene is down-regulated in EBV-associated nasopharyngeal carcinoma

Journal of Pathology

Volumn 217, Issue 3, 2009, Pages 345-352

  Bose, Shikha ^a   Yap, Lee Fah ^b   Fung, Matthew ^a   Starzcynski, Jane ^e   Saleh, Amyza ^b   Morgan, Susan ^a   Dawson, Christopher ^a   Chukwuma, Marilyn B ^a   Maina, Esther ^a   Buettner, Maike ^d   Wei, Wenbin ^a   Arrand, John ^a   Lim, Paul V H ^c   Young, Lawrence S ^a   Teo, Soo Hwang ^b   Stankovic, Tatjana ^a   Woodman, Ciaran B J ^a   Murray, Paul G ^a,e  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^c Tung Shin Hospital   (Malaysia)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

ATM; Epstein Barr virus; Nasopharyngeal carcinoma

Indexed keywords

ATM PROTEIN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA DAMAGE; EPSTEIN BARR VIRUS; GAMMA IRRADIATION; GENE CONTROL; GENE MUTATION; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; CASE CONTROL STUDY; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METHODOLOGY; NASOPHARYNX TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VIROLOGY; VIRUS INFECTION;

ADENOCARCINOMA; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; NASOPHARYNGEAL NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS; TUMOR VIRUS INFECTIONS;

EID: 60549116871     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2487     Document Type: Article

References (31)

1. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell 2004;5:423-428.
2. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005;365:2041-2054.
3. Fang FM, Chiu HC, Kuo WR, Wang CJ, Leung SW, Chen HC, et al. Health-related quality of life for nasopharyngeal carcinoma patients with cancer-free survival after treatment. Int J Radiat Oncol Biol Phys 2002;53:959-968.
4. Millan AS, Pow EH, Leung WK, Wong MC, Kwong DL. Oral health-related quality of life in southern Chinese following radiotherapy for nasopharyngeal carcinoma. J Oral Rehab 2004;31:600-608.
5. Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004;22:2643-2653.
6. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995;333:693- 698.
7. Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988;69:1051-1065.
8. Bell AI, Groves K, Kelly GL, Croom-Carter D, Hui E, Chan AT, et al. Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol 2006;87:2885-2890.
9. Tao Q, Young LS, Woodman CB, Murray PG. Epstein-Barr virus (EBV) and its associated human cancers - genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci 2006;11:2672-2713.
10. Tsao SW, Wang X, Liu Y, Cheung YC, Feng H, Zheng Z, et al. Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim Biophys Acta 2002;1590:150-158.
11. Stewart S, Dawson CW, Takada K, Curnow J, Moody CA, Sixbey JW, et al. Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF- KB transcription factor pathway. Proc Natl Acad Sci USA et al. 2004;101:15730-15735.
12. Starczynski J, Simmons W, Flavell JR, Byrd PJ, Stewart GS, Kullar HS, et al. Variations in ATM protein expression during normal lymphoid differentiation and among B cell-derived neoplasias. Am J Pathol 2003;163:423-432.
13. Reynolds GM, Billingham LJ, Gray LJ, Flavell JR, Najafipour S, Crocker J, et al. 1L-6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease Br J Haematol 2002;118:195-201.
14. Heussinger N, Büttner M, Ott G, Brachtel E, Pilch BZ, Kremmer E, et al. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopha ryngeal carcinoma. J Pathol 2004;203:696-699.
15. Stankovic T, Stewart GS, Fegan C, Biggs P, Last J, Byrd PJ, et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 2002;99:300-309.
16. Bose S, Starczynski J, Chukwuma M, Baumforth K, Wei W, Morgan S, et al. Down-regulation of ATM protein in HRS cells of nodular sclerosis Hodgkin's lymphoma in children occurs in the absence of ATM gene inactivation. J Pathol 2007;213:329-336.
17. Austen B, Powell JE, Alvi A, Edwards I, Hooper L, Starczyn ski J, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005;106:3175-3182.
18. Buscemi G, Savio C, Zannini L, Micciche F, Masnada D, Nakanishi M, et al. Chk2 activation dependence on Nbsl after DNA damage. Mol Cell Biol 2001;21:5214-5222.
19. Chao C, Saito S, Anderson CW, Appella E, Xu Y. Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage. Proc Natl Acad Sci USA 2000;97:11936-11941.
20. Gatei M, Young D, Cerosaletti KM, Desai-Mehta A, Spring K, Kozlov S, et al. ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nat Genet 2000;25:115-119.
21. Gatei M, Scott SP, Filippovitch I, Soronika N, Lavin MF, Weber B, et al. Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res 2000;60:3299-3304.
22. Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukaemia and lymphoma in ataxia telangiectasia. Blood 1996;87:423-438.
23. He Y, Chen Q, Li B. ATM in oral carcinogenesis: association with clinicopathological features. J Cancer Res Clin Oncol. 2008;134:1013-1020.
24. Fang Y, Guan X, Guo Y, Sham J, Deng M, Liang Q, et al. Analysis of genetic alterations in primary nasopharyngeal carcinoma by comparative genomic hybridization. Genes Chromosomes Cancer 2001;30:254-260.
25. Chen YJ, Ko JY, Chen PJ, Shu CH, Hsu MT, Tsai SF, et al. Chromosomal aberrations in nasopharyngeal carcinoma analyzed by comparative genomic hybridization. Genes Chromosomes Cancer 1999;25:169-175.
26. Bolt J, Vo QN, Kim WJ, McWhorter AJ, Thomson J, Hagensee ME, et al. The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. Oral Oncol 2005;41:1013-1020.
27. Dutton A, Woodman CB, Chukwuma MB, Last JIK, Wei W, Vockerodt M, et al. BMI-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood 2007;109:2597-2603.
28. Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25:5448-5457.
29. Stankovic T, Hubank M, Cronin D, Stewart GS, Fletcher D, Bigneil CR, et al. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood 2004;103:291-300.
30. Bryant HE, Helleday T. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents. Biochem Soc Trans 2004;32:959- 961.
31. Bryant HE, Helleday T. Inhibition of poly(ADP-ribose) poly merase activates ATM which is required for subsequent homolo gous recombination repair. Nucleic Acids Res 2006;34:1685-1691.